The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XGN | +210.69% | -39.08% | -9.43% | -52% |
| S&P | +13.19% | +87.83% | +13.42% | +124% |
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.24M | 37.9% |
| Gross Profit | $10.08M | 44.3% |
| Gross Margin | 58.43% | 2.6% |
| Market Cap | $241.82M | 350.1% |
| Market Cap / Employee | $1.16M | 0.0% |
| Employees | 209 | 16.8% |
| Net Income | -$7.09M | -41.0% |
| EBITDA | -$2.49M | 41.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $35.65M | 61.8% |
| Accounts Receivable | $11.09M | 18.2% |
| Inventory | 3.5 | 20.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $25.16M | 15.5% |
| Short Term Debt | $3.01M | 69.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.78% | -3.4% |
| Return On Invested Capital | -42.32% | -3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.67M | 214.9% |
| Operating Free Cash Flow | $2.94M | 235.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.58 | 6.64 | 19.57 | 11.49 | 173.20% |
| Price to Sales | 1.36 | 1.17 | 2.50 | 3.96 | 291.80% |
| Price to Tangible Book Value | 5.58 | 6.64 | 19.57 | 11.49 | 173.20% |
| Enterprise Value to EBITDA | -25.90 | -26.96 | -65.78 | -98.32 | 619.87% |
| Return on Equity | -93.8% | -117.5% | -87.9% | -122.8% | 46.45% |
| Total Debt | $23.36M | $23.44M | $25.20M | $28.17M | 19.59% |
No podcast episodes available.
XGN earnings call for the period ending June 30, 2022.
XGN earnings call for the period ending March 31, 2022.
XGN earnings call for the period ending December 31, 2021.
XGN earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
